The clinical significance of ebv DNA in the plasma and peripheral blood mononuclear cells of patients with or without ebv diseases

Blood

Volumn 127, Issue 16, 2016, Pages 2007-2017

  Kanakry, Jennifer A ^a   Hegde, Aparna M ^a   Durand, Christine M ^a   Massie, Allan B ^a   Greer, Amy E ^a   Ambinder, Richard F ^a   Valsamakis, Alexandra ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS DNA; UNCLASSIFIED DRUG; VIRUS DNA;

ARTICLE; COHORT ANALYSIS; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE DOSAGE; HUMAN; IMMUNOCOMPROMISED PATIENT; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; VIRUS DETECTION; BLOOD; EPSTEIN-BARR VIRUS INFECTIONS; GENETICS; MONONUCLEAR CELL; PROGNOSIS; VIROLOGY; VIRUS LOAD;

COHORT STUDIES; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; GENE DOSAGE; HERPESVIRUS 4, HUMAN; HUMANS; LEUKOCYTES, MONONUCLEAR; PROGNOSIS; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 84965075984     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-09-672030     Document Type: Article

References (43)

1. Meerbach A, Wutzler P, H afer R, Zintl F, Gruhn B. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post- Transplant lymphoproliferative disease. J Med Virol. 2008;80(3):441-454.
2. Tsai DE, Douglas L, Andreadis C, et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: Results of a two- Arm prospective trial. Am J Transplant. 2008;8(5): 1016-1024.
3. Wagner HJ, Fischer L, Jabs WJ, Holbe M, Pethig K, Bucsky P. Longitudinal analysis of Epstein-Barr viral load in plasma and peripheral blood mononuclear cells of transplanted patients by real- Time polymerase chain reaction. Transplantation. 2002;74(5):656-664.
4. van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBVlymphoproliferative disease following T-cell- depleted SCT. Blood. 2001;98(4):972-978.
5. Baldanti F, Grossi P, Furione M, et al. High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol. 2000;38(2):613-619.
6. Hakim H, Gibson C, Pan J, et al. Comparison of various blood compartments and reporting units for the detection and quantification of Epstein-Barr virus in peripheral blood. J Clin Microbiol. 2007; 45(7):2151-2155.
7. Wagner HJ, Wessel M, Jabs W, et al. Patients at risk for development of posttransplant lymphoproliferative disorder: Plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real- Time quantitative polymerase chain reaction. Transplantation. 2001;72(6):1012-1019.
8. Fafi-Kremer S, Brengel-Pesce K, Bargùes G, et al. Assessment of automated DNA extraction coupled with real- Time PCR for measuring Epstein-Barr virus load in whole blood, peripheral mononuclear cells and plasma. J Clin Virol. 2004; 30(2):157-164.
9. Clave E, Agbalika F, Bajzik V, et al. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: Relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation. 2004;77(1):76-84.
10. Ruf S, Behnke-Hall K, Gruhn B, et al. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation. J Clin Virol. 2012;53(3):186-194.
11. Yang J, Tao Q, Flinn IW, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood. 2000;96(13): 4055-4063.
12. Cui Q, Gandhi MK. Whole blood EBV-DNA: A surrogate for immune dysfunction in aggressive lymphoma? [published online ahead of print October 8, 2015]. Leuk Lymphoma. doi:10.3109/10428194.2015.1087522.
13. Tsai DE, Luskin MR, Kremer BE, et al. A pilot trial of quantitative Epstein-Barr virus polymerase chain reaction in patients undergoing treatment for their malignancy: Potential use of Epstein-Barr virus polymerase chain reaction in multiple cancer types. Leuk Lymphoma. 2015;56(5):1530-1532. 14.
14. Burighel N, Ghezzi S, Nozza S, et al. Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy. Haematologica. 2006;91(2): 244-247.
15. Stevens SJ, Pronk I, Middeldorp JM. Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. J Clin Microbiol. 2001;39(4):1211-1216.
16. Zhang W, Chen Y, Chen L, et al. The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: The dawn of a new era?: A systematic review and meta- Analysis of 7836 cases. Medicine (Baltimore). 2015;94(20): E845.
17. Chan KC, Hung EC, Woo JK, et al. Early detection of nasopharyngeal carcinoma by plasma Epstein- Barr virus DNA analysis in a surveillance program. Cancer. 2013;119(10):1838-1844.
18. Juvonen E, Aalto S, Tarkkanen J, Volin L, Hedman K, Ruutu T. Retrospective evaluation of serum Epstein Barr virus DNA levels in 406 allogeneic stem cell transplant patients. Haematologica. 2007;92(6):819-825.
19. Kim SJ, Hong M, Do IG, et al. Serum survivin and vascular endothelial growth factor in extranodal NK/T-cell lymphoma, nasal type: implications for a potential new prognostic indicator. Haematologica. 2015;100(3):e106-e109.
20. Jones K, Vari F, Keane C, et al. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res. 2013;19(3):731-742.
21. Kanakry JA, Li H, Gellert LL, et al. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood. 2013;121(18):3547-3553 .
22. Wang L, Wang H, Wang JH, et al. Post- Treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase. Oncotarget. 2015;6(30):30317-30326.
23. Kwong YL, Pang AW, Leung AY, Chim CS, Tse E. Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance. Leukemia. 2014;28(4):865-870.
24. Jones K, Nourse JP, Keane C, et al. Tumorspecific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma. Am J Hematol. 2012; 87(3):258-265.
25. Walton AH, Muenzer JT, Rasche D, et al. Reactivation of multiple viruses in patients with sepsis. PLoS One. 2014;9(2):e98819.
26. Martelius T, Lappalainen M, Aalto SM, Nihtinen A, Hedman K, Anttila VJ. Clinical characteristics, outcome and the role of viral load in nontransplant patients with Epstein-Barr viraemia. Clin Microbiol Infect. 2010;16(6):657-662.
27. Fan H, Kim SC, Chima CO, et al. Epstein-Barr viral load as a marker of lymphoma in AIDS patients. J Med Virol. 2005;75(1):59-69.
28. Ryan JL, Fan H, Swinnen LJ, et al. Epstein-Barr Virus (EBV) DNA in plasma is not encapsidated in patients with EBV-related malignancies. Diagn Mol Pathol. 2004;13(2):61-68.
29. Chan KC, Zhang J, Chan AT, et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res. 2003;63(9): 2028-2032.
30. Babcock GJ, Decker LL, Freeman RB, Thorley- Lawson DA. Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med. 1999; 190(4):567-576.
31. Calattini S, Sereti I, Scheinberg P, Kimura H, Childs RW, Cohen JI. Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno- FISH. Blood. 2010;116(22):4546-4559.
32. Shao JY, Zhang Y, Li YH, et al. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma. Anticancer Res. 2004;24(6): 4059-4066.
33. Loginov R, Aalto S, Piiparinen H, et al. Monitoring of EBV-DNAemia by quantitative real- Time PCR after adult liver transplantation. J Clin Virol. 2006; 37(2):104-108.
34. Wada K, Kubota N, Ito Y, et al. Simultaneous quantification of Epstein-Barr virus, cytomegalovirus, and human herpesvirus 6 DNA in samples from transplant recipients by multiplex real- Time PCR assay. J Clin Microbiol. 2007;45(5): 1426-1432.
35. Gandhi MK, Lambley E, Burrows J, et al. Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res. 2006;12(2):460-464.
36. Hohaus S, Santangelo R, Giachelia M, et al. The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkinlymphoma. Clin Cancer Res. 2011;17(9): 2885-2892.
37. Wang ZY, Liu QF, Wang H, et al. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal- Type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood. 2012;120(10): 2003-2010.
38. Suzuki R, Yamaguchi M, Izutsu K, et al; NK-cell Tumor Study Group. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 2011;118(23): 6018-6022.
39. Machado AS, Da Silva Robaina MC, Magalhães De Rezende LM, et al. Circulating cell-free and Epstein-Barr virus DNA in pediatric B-non- Hodgkin lymphomas. Leuk Lymphoma. 2010; 51(6):1020-1027.
40. Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004;104(1): 243-249.
41. Morishima S, Nakamura S, Yamamoto K, et al. Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56(4):1072-1078.
42. Suwiwat S, Pradutkanchana J, Ishida T, Mitarnun W. Quantitative analysis of cell-free Epstein-Barr virus DNA in the plasma of patients with peripheral T-cell and NK-cell lymphomas and peripheral T-cell proliferative diseases. J Clin Virol. 2007;40(4):277-283.
43. Teramura T, Tabata Y, Yagi T, Morimoto A, Hibi S, Imashuku S. Quantitative analysis of cell-free Epstein-Barr virus genome copy number in patients with EBV- Associated hemophagocytic lymphohistiocytosis. Leuk Lymphoma. 2002; 43(1):173-179.